Attached files

file filename
EX-99.1 - AUDITED BALANCE SHEET AS OF OCTOBER 2, 2020 - Beauty Health Coea127950ex99-1_vesper.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 8, 2020 (October 2, 2020)

 

Vesper Healthcare Acquisition Corp.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39565   85-1908962
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

1819 West Avenue

Bay 2

Miami Beach, FL 33139

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (786) 216-7037

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  Name of each exchange on which registered
         
Units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant   VSPRU   The Nasdaq Stock Market LLC
         
Class A Common Stock, par value $0.0001 per share   VSPR   The Nasdaq Stock Market LLC
         
Warrants, each exercisable for one share of Class A Common Stock at a price of $11.50   VSPRW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company þ

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 8.01. Other Events.

 

On October 2, 2020, Vesper Healthcare Acquisition Corp. (the “Company”) consummated its initial public offering (the “IPO”) of 46,000,000 units (the “Units”), including 6,000,000 Units purchased by the underwriters as a result of the full exercise of their over-allotment option. Each Unit consists of one share of Class A common stock of the Company, par value $0.0001 per share (“Class A Common Stock”) and one-third of one redeemable warrant of the Company (each whole warrant, a “Warrant”), with each whole Warrant entitling the holder thereof to purchase one share of Class A Common Stock for $11.50 per share. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $460,000,000.

 

On October 2, 2020, simultaneously with the consummation of the IPO, the Company issued in a private sale (the “Private Placement”) 9,333,333 warrants (the “Private Placement Warrants”) to BLS Investor Group LLC, for $14,000,000.

 

A total of $460,000,000, comprised of $450,800,000 of the proceeds from the IPO (which amount includes $16,100,000 of the underwriters’ deferred underwriting commissions) and $9,200,000 of the proceeds of the sale of the Private Placement Warrants, was placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company, acting as trustee.

 

An audited balance sheet as of October 2, 2020 reflecting receipt of the proceeds upon consummation of the IPO and the Private Placement has been issued by the Company and is included as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)  Exhibits

 

Exhibit No.   Description
99.1   Audited Balance Sheet as of October 2, 2020.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Vesper Healthcare Acquisition Corp.
     
  By: /s/ Brenton L. Saunders
    Name:   Brenton L. Saunders
    Title: Chief Executive Officer
     
Dated: October 8, 2020    

 

2